S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

Autor: Edward V. Loftus, Millie Long, Elyssa Ott, Christopher Gasink, Thomas Baker, Bridget Goodwin, Ye Miao, Subrata Ghosh

Publikováno v: American Journal of Gastroenterology. 117:e675-e675

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3189826e221842e4ba70f2538f377490
https://doi.org/10.14309/01.ajg.0000860368.55128.7d

S1290 Efficacy, Safety, and Pharmacokinetics of Infliximab Dose Escalation in Pediatric Patients With Crohn’s Disease or Ulcerative Colitis: An Analysis of the DEVELOP Registry

Autor: Harland S. Winter, Omoniyi J. Adedokun, Robert N. Baldassano, James Markowitz, Anne M. Griffiths, Elyssa Ott, Long-Long Gao, Tony Ma, Christopher Busse, Sibylle Koletzko, James L. Izanec, Subra Kugathasan, Christopher Gasink, Marla Dubinsky, Richard B. Colletti, Frank M. Ruemmele, Jeffrey S. Hyams

Publikováno v: American Journal of Gastroenterology. 116:S592-S593

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67fc1e4344be4df93d0678ed78dc044e
https://doi.org/10.14309/01.ajg.0000778692.42211.5f

Tu1438: LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN'S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Autor: Edward V. Loftus, Scott D. Lee, Remo Panaccione, Elyssa Ott, Christopher Gasink, Ye Miao, Colleen W. Marano, Subrata Ghosh

Publikováno v: Gastroenterology. 162:S-960

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d62151a2ec38aa9edeadb79ca2805ddc
https://doi.org/10.1016/s0016-5085(22)62276-5

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

Autor: Subrata Ghosh, Bruce E. Sands, Elyssa Ott, Brian G. Feagan, Christopher Gasink, Silvio Danese, Colleen Marano, Yiying Zhou, Sheri Volger, Thomas Baker, William J. Sandborn, Christopher D. O'Brien, Ilia Tikhonov

Publikováno v: Inflammatory Bowel Diseases

Background Ustekinumab is currently approved globally in Crohn’s disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn’s disease and UC phase 3 programs had similar study designs, f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f1a6e5ae0f123f2f0af0dd0d8c3f9ff
https://pubmed.ncbi.nlm.nih.gov/33511983

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Autor: Soumya D. Chakravarty, Kamyar Farahi, Zijiang Yang, Lianne S. Gensler, Bruce Strober, Subrata Ghosh, Elyssa Ott, Chris Gasink, P. Ramachandran

Publikováno v: Drug safety, vol 42, iss 6
Drug Safety
Ghosh, Subrata; Gensler, Lianne S; Yang, Zijiang; Gasink, Chris; Chakravarty, Soumya D; Farahi, Kamyar; et al.(2019). Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.. Drug safety. doi: 10.1007/s40264-019-00797-3. UCSF: Retrieved from: http://www.escholarship.org/uc/item/5mj3g2mw

INTRODUCTION:Theoretical risks of biologic agents remain under study. OBJECTIVE:The aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials. METHODS:Patients had moderate-to-severe plaque psoriasis, active psor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b95ad2974cc263635aadc1872d246990
https://escholarship.org/uc/item/5mj3g2mw